Vesalio Attains Key FDA Clinical Study Milestone

Share on facebook
Share on twitter
Share on linkedin
Vesalio Attains Key FDA Clinical Study Milestone


Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL(1) clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid…

Source

Leave a Replay

Ads by Alkali

Recent Posts

Ads by Alkali

Follow Us